PHARMACOKINETICS (PK) OF FENOFIBRIC ACID AND ROSUVASTATIN IN SUBJECTS WITH MILD TO MODERATE RENAL IMPAIRMENT.

被引：0
|
作者：
Zhu, T. [1 ]
Williams, L. [1 ]
Awni, W. [1 ]
Smith, W. [2 ]
Locke, C. [1 ]
Pradhan, R. [1 ]
机构：
[1] Abbott Labs, Abbott Pk, IL 60064 USA
[2] New Orleans Ctr Clin Res, Knoxville, TN USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 87卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [41] Pharmacokinetics of eslicarbazepine acetate in patients with renal impairment.
    Almeida, Luis
    Potgieter, J. Henk
    Maia, Joana
    Soares-da-Silva, P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09): : 1193 - 1193
  • [42] EFFECT OF FIMASARTAN ON PHARMACOKINETICS IN PATIENTS WITH RENAL IMPAIRMENT.
    Kim, S.
    Shin, D.
    Kim, Y. S.
    Cho, S. H.
    Jang, I. J.
    Lee, H.
    Yu, K. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S72 - S72
  • [43] Pharmacokinetics of oral maribavir, a novel anti-cytomegalovirus agent, in subjects with renal impairment.
    Swan, Suzanne
    Smith, William
    Marbury, Thomas
    Schumacher, Mary
    Dougherty, Carolyn
    Mico, Bruce
    Villano, Stephen
    BLOOD, 2006, 108 (11) : 810A - 811A
  • [44] Pharmacokinetics and Pharmacodynamics of Tigulixostat in Participants with Mild, Moderate, and Severe Renal Impairment
    Kumar, Ashish
    Hariri, Ali
    Lee, Yunjung
    Lee, Minhyung
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2213 - 2215
  • [45] Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment
    Dale, Glenn E.
    Halabi, Atef
    Petersen-Sylla, Marc
    Wach, Achim
    Zwingelstein, Christian
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (09)
  • [46] Pharmacokinetics of dexketoprofen trometamol in subjects with mild and moderate chronic renal insufficiency
    Valles, J.
    Artigas, R.
    Mas, M.
    Crea, A.
    Mueller, F.
    Paredes, I.
    Capriati, A.
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2006, 28 : 21 - 28
  • [47] Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment
    Turncliff, RZ
    Dunbar, JL
    Dong, QM
    Silverman, BL
    Ehrich, EW
    Dilzer, SC
    Lasseter, KC
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (11): : 1259 - 1267
  • [48] Pharmacokinetics and Safety of Aclidinium Bromide, a Novel, Long-Acting Antimuscarinic, in Subjects with Renal Impairment.
    Schmid, K.
    Pascual, S.
    Gil, E. Garcia
    Ortiz, S.
    Jansat, J. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [49] Pharmacodynamics and pharmacokinetics of DX-9065a in renal impairment.
    Depasse, F
    Kunitada, S
    Busson, J
    Haque, N
    Samama, MM
    BLOOD, 2003, 102 (11) : 121B - 121B
  • [50] Lucerastat, an iminosugar for substrate reduction therapy: pharmacokinetics, tolerability, and safety in subjects with mild, moderate, and severe renal function impairment
    Guerard, Nicolas
    Zwingelstein, Christian
    Dingemanse, Jasper
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S59 - S59
12345